Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company. They will develop and commercialize novel RNA-editing therapies using Rznomics’ proprietary trans-splicing ribozyme platform. The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss.  Rznomics will conduct ear...